磷霉素对美国当代细菌分离株进行测试时的活性。
Activity of fosfomycin when tested against US contemporary bacterial isolates.
作者信息
Flamm Robert K, Rhomberg Paul R, Watters Amy A, Sweeney Kim, Ellis-Grosse Evelyn J, Shortridge Dee
机构信息
JMI Laboratories, North Liberty, Iowa, USA.
JMI Laboratories, North Liberty, Iowa, USA.
出版信息
Diagn Microbiol Infect Dis. 2019 Feb;93(2):143-146. doi: 10.1016/j.diagmicrobio.2018.08.010. Epub 2018 Aug 28.
Fosfomycin and comparators were susceptibility tested against over 2200 contemporary clinical isolates from US medical centers. Fosfomycin was active against Enterobacterales (MIC, 4/16 μg/mL), including multidrug-resistant isolates. Potent activity was exhibited against gram-positive organisms, including Staphylococcus aureus (MIC, 4/8 μg/mL). Fosfomycin may provide a promising alternative option for treatment of infections where resistant bacteria may occur.
对来自美国医疗中心的2200多株当代临床分离菌株进行了磷霉素及对照药物的药敏试验。磷霉素对肠杆菌科细菌（最低抑菌浓度为4/16μg/mL）具有活性，包括多重耐药菌株。对革兰氏阳性菌也表现出强效活性，包括金黄色葡萄球菌（最低抑菌浓度为4/8μg/mL）。对于可能出现耐药菌的感染治疗，磷霉素可能提供一种有前景的替代选择。
Zotero 插件